Navigation Links
PSA Test for Prostate Cancer Doesn't Save Lives: Study
Date:1/9/2012

By Steven Reinberg
HealthDay Reporter

FRIDAY, Jan. 6 (HealthDay News) -- Annual screening for prostate cancer doesn't save lives, finds a new study that is unlikely to quell the controversy surrounding routine prostate specific antigen (PSA) screening.

"Organized prostate cancer screening when done in addition to whatever background testing exists in the population does not result in any apparent benefit, but does result in harm from false positives and over-diagnosis," said lead researcher Philip Prorok, from the Division of Cancer Prevention at the U.S. National Cancer Institute.

"Men considering prostate cancer screening should be fully informed of the implications of such testing before making a decision," he added.

Experts have disagreed for some time on whether the blood test saves lives or results in over-diagnosis and over-treatment. The new findings, which extend prior results out to 13 years of follow-up, are published in the Jan. 6 online edition of the Journal of the National Cancer Institute.

The study followed men enrolled in the Prostate, Lung, Colorectal and Ovarian Cancer Screening (PLCO) Trial from 1993 to 2009, comparing results for a group of men who had undergone screening with those for men who hadn't had testing. The men were 55 to 74 years old.

One group had PSA screening every year for six years and a digital rectal examination every year for four years. The other men had regular care, which in some cases included screening if requested by the patient or doctor.

Compared to men getting usual care, the screened men had a 12 percent relative increase in prostate cancer but a slightly lower rate of high-grade cancer.

However, no difference in deaths was seen between the two groups.

This finding held true even after age, screening before the trial and other medical conditions were taken into account, the researchers said.

Prorok said that better treatment for prostate cancer may explain the similar mortality results.

Among prostate cancer patients, death from other causes was somewhat higher in the screened group (10.7 percent of 4,250 men with prostate cancer) compared to the usual care group (9.9 percent of 3,815 men with prostate cancer).

This indicates men who underwent PSA screening were over-diagnosed, meaning the test picked up slow-growing tumors that probably weren't lethal, the researchers said.

"PSA testing and digital rectal examination screening as conducted in this trial did not reduce prostate cancer mortality, but there was a persistent excess of prostate cancer cases in the screened arm, suggesting over-diagnosis of prostate cancer," Prorok said.

Some prostate cancer experts disagree with the authors' conclusions.

Dr. Anthony D'Amico, chief of radiation oncology at Brigham and Women's Hospital in Boston, said the results are invalid because the trial was flawed.

According to D'Amico, 52 percent of those who received usual care had a PSA screening. "That's a serious issue which makes it very hard for the study to show if any benefit exists for PSA screening," he said.

Also, 15 percent of those who were supposed to get PSA screening never did, D'Amico said. "So what you've got is a screening study in which 85 percent of the people got PSA screened on the screening arm and 52 percent got screened on the control arm, which makes it impossible to ever measure a difference," he said.

Men should ignore this study, "because it has no relevance to PSA screening," D'Amico said.

D'Amico said he has more confidence in the results of a European study published in 2009 in the New England Journal of Medicine, which showed a 20 percent reduction in cancer mortality with PSA screening.

Men who can benefit most from screening are those at risk for prostate cancer, particularly men who have a family history of prostate cancer, African Americans and men over 60, D'Amico said.

Prorok acknowledged that the PLCO trial wasn't perfect. "Nonetheless, the contamination was not enough to eliminate the early diagnosis of prostate cancers nor the persistent excess of cancers," he said.

PLCO provides information about over-diagnosis, Prorok added. "Even if the contamination did dilute a benefit compared to no screening, the result of no mortality difference between the arms in PLCO could be interpreted to suggest that more intensive screening is not beneficial but does result in harm," he said.

More information

For more information on prostate cancer, visit the American Cancer Society.

SOURCES: Philip C. Prorok, Ph.D., Division of Cancer Prevention, U.S. National Cancer Institute; Anthony D'Amico, M.D., Ph.D., chief, radiation oncology, Brigham and Women's Hospital, Boston; Jan. 6, 2012, Journal of the National Cancer Institute, online


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Advance Toward Test for Aggressive Prostate Cancer
2. DASH FOR DAD Race Series Coming to 11 Cities to Raise Prostate Cancer Awareness
3. Jim Huber to Serve as National Spokesman for Know Your Score: Fight Prostate Campaign at Myrtle Beach Golf Holiday in August
4. Few differences in outcomes between open and laparoscopic prostate surgery
5. Two Surgical Methods Equally Successful for Prostate Cancer
6. Genetic Mutation Linked to Prostate Cancer in Blacks
7. Statins May Benefit Prostate Cancer Patients
8. Demand For Mobile Prostate Cancer Brachytherapy Vendor Programs Continues Into 2010
9. Be a Star Athlete in the Fight Against Prostate Cancer
10. Do men with early prostate cancer commit suicide more frequently?
11. Effective prostate cancer treatment discovery
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
 PSA Test for Prostate Cancer Doesn't Save Lives: Study
(Date:6/20/2017)... ... June 20, 2017 , ... With certifications and experience that puts them at ... Adam and Hal Kimowitz are currently accepting new patients at their practice for these ... for some patients, which is why they offer the latest in modern dental techniques ...
(Date:6/20/2017)... Linda, Ca (PRWEB) , ... June 20, 2017 ... ... of alternative polyA sites. To understand their regulatory principles, the research team developed ... mRNA-Seq, iCLIP and RNA motif analyses. This reveals at nucleotide resolution the ‘RNA ...
(Date:6/20/2017)... ... June 20, 2017 , ... ... industry has been selected as the partner of choice by Amtrak to fulfill ... service that provides medium- and long-distance intercity service in the contiguous United States. ...
(Date:6/20/2017)... ... June 20, 2017 , ... Uniworld Boutique River ... aboard the line’s latest all-inclusive boutique ship, S.S. Joie de Vivre . What ... specifically for cruising France’s Seine River and designed small enough to dock directly in ...
(Date:6/20/2017)... , ... June 20, 2017 , ... The law firm ... on his installation as the president of the DuPage County Bar Association’s Board of ... Installation Dinner June 9 at the Drake in Oak Brook. Momkus McCluskey Roberts LLC ...
Breaking Medicine News(10 mins):
(Date:6/5/2017)... , June 5, 2017 Kohll,s Pharmacy ... the United States . The Raizer is ... a fallen person up to an almost-standing position ... and operated by one assistant and does not ... is simple enough that a child can operate it, ...
(Date:6/2/2017)...  NxStage Medical, Inc. (Nasdaq:  NXTM), a leading medical technology company ... demonstrating positive biochemical outcomes related to more frequent hemodialysis ... will be presented at the ERA-EDTA Congress being held ... . The research was conducted by ... Europe (KIHDNEy) Cohort team ...
(Date:5/30/2017)... DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health ... it will be presenting at the 7th annual LD Micro Invitational ... Raphael , CEO, of DarioHealth will be giving the presentation and ... June 6th & 7th, 2017 at the Luxe Sunset Bel Air ... space. About LD Micro LD ...
Breaking Medicine Technology: